Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]-ITI-1284 in Healthy Men
NCT06786286Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deulumateperone in dementia-related psychosis (DRP), generalized anxiety disorder (GAD) and Alzheimer's disease (AD), sponsored by Intra-Cellular Therapies. Primary endpoints: Mass balance recovery of total radioactivity in urine and feces combined, Pharmacokinetics: AUC0-t for total radioactivity and 5 more. Started Jan 2025; status: completed.
02
Drugs
deulumateperone
03
Conditions
dementia-related psychosis (DRP)generalized anxiety disorder (GAD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06786286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786286.